Trial Profile
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary) ; Varicella zoster virus vaccine live (Primary)
- Indications Herpes zoster; Varicella zoster virus infections
- Focus Pharmacodynamics
- Acronyms BMS-188667
- 12 Feb 2024 Planned End Date changed from 1 Sep 2025 to 1 Sep 2026.
- 12 Feb 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
- 12 Feb 2024 Status changed from recruiting to active, no longer recruiting.